Chris Meyer, with over 25 years of experience in biotherapeutics/cell therapy operations is a strategy & business operations leader who has led high-impact CMC teams/initiatives/functions for Fortune 500 and emerging biotherapeutics companies. He leverages a unique blend of CMC program management, technical operations, finance, and commercialization expertise to address evolving business needs.

Before consulting, he held Director of Strategic Operations roles at Atara Biotherapeutics, Kite Pharma (a Gilead division), and Takeda (formerly Baxter/Baxalta/Shire) in Product and CMC Program Lead roles for clinical and commercial stage products.

He supports clients through operations and supply planning, strategic decision analysis, CMC program planning/management, optimization initiatives and business continuity planning.

EDUCATION

Indiana University – Bloomington
BA, Accounting